TEYLOR MARTINEZ: Open Payments
NPI 1396361630 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$784 in 34 payments from 16 companies in 2025. Trend: 2023 $428 · 2024 $795 · 2025 $784
Food & beverage: $784
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 10 | $213 |
| Janssen Biotech, Inc. | 5 | $134 |
| Merck Sharp & Dohme LLC | 3 | $68 |
| SOBI, INC | 2 | $55 |
| Pharmacosmos Therapeutics Inc. | 2 | $51 |
| Genentech USA, Inc. | 2 | $41 |
| E.R. Squibb & Sons, L.L.C. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| BeOne Medicines USA, Inc. | 1 | $26 |
| Incyte Corporation | 1 | $23 |
Products named: Enhertu, DATROWAY, TECVAYLI, MONOFERRIC, KEYTRUDA, RYBREVANT, Gamifant, OPDIVO.
Industry payments across DC — which companies pay providers there.
